Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Guidance and Visibility -- Ignore unavailable to you. Want to Upgrade?

To: SusieQ1065 who wrote (61405)	7/21/2002 4:34:06 PM
From: SusieQ1065	Read Replies (1) \| Respond to of 208838

Play of the Day - Put, Sunday, 07/21/2002 -------------------------------------------------------------------------------- UPS - United Parcel Service $67.00 (+5.74 last week) Company Summary: United Parcel Service is an express carrier package delivery company and a global provider of specialized transportation and logistics services. The company delivers packages each business day for 1.8 million customers to six million consignees. In 2001, UPS delivered an average of more than 13.5 million pieces per day worldwide. The company's primary business is the time-definite delivery of packages and documents throughout the United States and in over 200 other countries and territories. UPS has established a vast global transportation infrastructure and developed a comprehensive portfolio of guaranteed delivery services and supports them with advanced technology. Play Description: The Americanization of the S&P500 finally reached completion on Friday, just one more factor adding to the volatility of a wild expiration Friday. All of the companies being added to the index saw heavy buying at the close, as funds were loathe to take on those positions any earlier due to the wild carnage in the broad markets. Shares of UPS had actually traded well for much of the week already, having moved up from the $0 level to just over $62 on Thursday. But the volatility became rather insane on Friday, with the stock trading in a widening pattern between $61.50-64.00. And that was before the huge surge in volume (more than 20 million shares) after the closing bell that traded at $67. With the broad market clearly in trouble and likely headed substantially lower next week, it seems a pretty safe conclusion that UPS will lose a lot of the luster it had going into Friday's close. We want to take advantage of the artificial surge to initiate new positions that will benefit as the stock falls back to earth. Given the large move after the close, technical levels are rather hard to gauge right here. Although it is worth noting that $67 is the site of resistance from April 2000, so it could very possibly be where the reversal occurs. Above there, we have heavy resistance at $70, so we'll set our stop slightly higher at $70.25. Of course, if the after hours action is irrelevant (like it often is), we could see the stock roll over at the $64 resistance level, and that would also provide for a solid entry into the play. After we see where the stock settles out on Monday, we'll be able better define the action plan and set a better level for our stop. BUY PUT AUG-65*UPS-TM OI= 686 at $2.75 SL=1.25 BUY PUT AUG-60 UPS-TL OI=3499 at $0.90 SL=0.50 Average Daily Volume = 3.31 mln

To: SusieQ1065 who wrote (61405)	7/21/2002 6:17:13 PM
From: Densiebj	Read Replies (1) \| Respond to of 208838

speaking of channels....symbol-FAST;start your channel at about October 2000 and take it to October 2001.stop it and extend it..look how it got ahead of its channel and now coming back down within the channel again; the bottom is in the 30-31 area d

To: SusieQ1065 who wrote (61405)	7/22/2002 7:36:23 AM
From: 2MAR$	Read Replies (2) \| Respond to of 208838

better to have not been short AMGN from friday , and 3-M reported this am ...(i knew you weren't ;-) FDA Approves Amgen's Aranesp(TM) For Anemia Associated With Chemotherapy - New Anemia Treatment Joins Amgen's Neulasta(TM) to Simplify Supportive Care for Cancer Patients Undergoing Chemotherapy - THOUSAND OAKS, Calif., July 22 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN), the world's largest biotechnology company, today announced that the U.S. Food and Drug Administration (FDA) has approved Aranesp(TM) (darbepoetin alfa) for the treatment of chemotherapy-induced anemia in patients with nonmyeloid malignancies. Aranesp is a recombinant erythropoietic protein (proteins that stimulate production of oxygen-carrying red blood cells) that requires fewer injections than existing treatment. Amgen revolutionized anemia treatment with the discovery of recombinant human erythropoietin in 1984, which led to the development of Epoetin alfa, currently marketed as EPOGEN(R)(i) and Procrit(R)(ii). Building on this heritage, Amgen created Aranesp, which was developed to simplify anemia management. Aranesp maintains its level in the blood approximately three times longer than Epoetin alfa, offering healthcare providers the ability to treat anemia related to chemotherapy with less-frequent dosing than the current standard of care. Less-frequent dosing results in fewer injections for patients. It allows patients and caregivers to spend less time scheduling injection visits, and will free up physicians and nurses to attend to other patients and work activity. "Anemia can take a tremendous toll on patients undergoing chemotherapy, often leaving them too weak to perform routine activities. In severe cases, anemia can force doctors to interrupt chemotherapy regimens," said Robert E. Smith, Jr., M.D., president of South Carolina Oncology Associates PA and an Aranesp investigator. "Aranesp not only helps correct anemia and maintain hemoglobin levels during chemotherapy, but also helps chemotherapy patients and their physicians overcome barriers that can hinder the delivery of current anemia treatment, notably the need for frequent office visits." This year, an estimated 1.2 million cancer patients will undergo cytotoxic chemotherapy in the United States; and approximately 800,000 (67%) will become anemic. Anemia is the shortage of oxygen-carrying red blood cells that fuel body function. Patients undergoing chemotherapy often suffer from anemia because chemotherapy not only attacks cancerous cells, but other cells in the body as well, including red blood cells. Aranesp(TM) stimulates the bone marrow to increase the production of red blood cells and has been shown to result in a clinically significant improvement of anemia associated with chemotherapy. Before Aranesp, physicians were limited to treating anemia associated with chemotherapy with frequent injections of Epoetin alfa or red blood cell transfusions. "Aranesp is an important development that will make it easier for oncologists to treat their chemotherapy patients' anemia," said Amgen chairman and chief executive officer Kevin Sharer. "Joining the once-per-chemotherapy- cycle dosed Neulasta(TM) (pegfilgrastim), Aranesp's simplified dosing regimen represents Amgen's next generation of powerful supportive care treatments for patients receiving chemotherapy. With Aranesp and Neulasta, Amgen is helping physicians, nurses and patients address two of the most serious complications of chemotherapy." Clinical studies showed that patients suffering from chemotherapy-related anemia who received Aranesp consistently reached target hemoglobin (red blood cell) levels. The studies showed Aranesp to be generally well-tolerated. Aranesp was approved by the FDA in September 2001 for the treatment of anemia associated with chronic renal failure, also known as chronic kidney disease, for patients on dialysis and patients not on dialysis. Aranesp is contraindicated in patients with uncontrolled hypertension. Erythropoietic therapies may increase the risk of thrombotic and other serious events; dose reductions are recommended if the hemoglobin increase exceeds 1.0 g/dL in any two-week period. The most commonly reported side effects in Aranesp trials were fatigue, edema, nausea, vomiting, diarrhea, fever, and dyspnea; no important differences were observed between Aranesp and Epoetin alfa. Neulasta(TM) was approved by the FDA in January 2002 for decreasing the incidence of infection as manifested by febrile neutropenia (neutropenia with fever) in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs. In clinical trials, the most common adverse event attributed to Neulasta therapy following combination chemotherapy in patients (n=465) with lymphoma and solid tumors was bone pain, reported in 26% of patients. The only serious adverse event not attributed to underlying disease or chemotherapy was a case of hypoxia. While not reported in patients receiving Neulasta, rare events of adult respiratory distress syndrome, splenic rupture, and sickle cell crisis have been reported in patients receiving the parent compound, Filgrastim. Amgen is a global biotechnology company that discovers, develops, manufactures and markets important human therapeutics based on advances in cellular and molecular biology.